ライフサイエンスコーパス: albendazole

1 andard treatment (single oral dose of 400 mg albendazole).

2 the current standard treatment (single-dose albendazole).

3 integrated treatment (both praziquantel and albendazole).

4 6% lower incidence of malaria infection than albendazole.

5 linical reports are compiled with a focus on albendazole.

6 in all six rounds of mass administration of albendazole.

7 es for praziquantel and two times higher for albendazole.

8 All patients received albendazole.

9 errupted, rather than continuous, courses of albendazole.

10 Surviving recipients received albendazole.

11 solubilize the insoluble benzimidazole drug albendazole.

12 The cure rate with albendazole (2.6%) and the egg-reduction rate with alben

13 g per treatment) against schistosomiasis and albendazole (400 mg per treatment) against soil-transmit

14 against C sinensis infection using 400 mg of albendazole (400 mg twice a day for 5 days and 400 mg tw

15 tin (200 ug/kg) and albendazole (400 mg), or albendazole (400 mg) and placebo.

16 habitants aged 2 years or older were offered albendazole (400 mg) every 6 months.

17 ral doses of ivermectin (150-200 mug/kg) and albendazole (400 mg), and those in the intervention grou

18 e single oral doses of moxidectin (8 mg) and albendazole (400 mg), ivermectin (200 ug/kg) and albenda

19 ndazole (400 mg), ivermectin (200 ug/kg) and albendazole (400 mg), or albendazole (400 mg) and placeb

20 tin (400 mug per kilogram of body weight) or albendazole (400 mg, active control) once a month for 3

21 azole (2.6%) and the egg-reduction rate with albendazole (45.0%; 95% CI, 32.0 to 56.4) were significa

22 thelmintic agents (mebendazole, 65 ng/L, and albendazole, 48 ng/L) could be identified in the two tox

23 plied to different milk samples, residues of albendazole (49mugkg(-1)), sulfamethazine (<LOQ) and meb

24 r intestinal parasites with a single dose of albendazole (600 mg), administered overseas before depar

25 00 mug/kg; diethylcarbamazine, 6 mg/kg; plus albendazole, a fixed dose of 400 mg) or with DA alone.

26 dentified a synergy between the anthelmintic albendazole (ABZ) and drugs depleting the filarial endos

27 bral Taenia solium cysticercosis with either albendazole (ABZ) or praziquantel (PZQ) is suboptimal.

28 per kilogram of body weight, plus 400 mg of albendazole, administered on consecutive days; oxantel p

29 In 2007-2016 mass ivermectin plus albendazole administration was implemented.

30 of coinfected children with praziquantel and albendazole affected schistosome- and hookworm-specific

31 of moxidectin alone and in combination with albendazole against T. trichiura and other STHs has not

32 miannual mass drug administration (MDA) with albendazole (ALB) alone on lymphatic filariasis (LF).

33 vestigated whether two common antiparasitics-albendazole (ALB) and metronidazole (MTZ)-significantly

34 thylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unknown.

35 The combination of ivermectin (IVM) and albendazole (ALB) has shown significant improvements in

36 rected treatment with praziquantel (PZQ) and albendazole (ALB) was analyzed in 17 villages of Mayuge

37 Ivermectin (IVM) plus albendazole (ALB), or IA, is widely used in mass drug ad

38 atment with ivermectin (IVM; 200 ug/kg) plus albendazole (ALB; 800 mg single dose) is superior to IVM

39 eatment with ivermectin (IVM; 200ug/kg) plus albendazole (ALB; 800mg single dose) is superior to IVM

40 1.4%), and whipworm (86.8% to 59.5%), while albendazole alone significantly reduced prevalence of ho

41 her three groups (20 [69%] placebo, 22 [76%] albendazole alone, 17 [61%] ivermectin alone remained po

42 per 20 microL blood among those who received albendazole alone; and from 13.7 to 0.3 per 20 microL bl

43 Albendazole, an oral drug currently used to treat parasi

44 locks of 100, we assigned patients to 440 mg albendazole and 40 mg/kg praziquantel (n=628), 440 mg al

45 le and 40 mg/kg praziquantel (n=628), 440 mg albendazole and a praziquantel-matching placebo (n=625),

46 ance to frontline anthelmintic drugs such as albendazole and ivermectin underscores the urgent need f

47 Albendazole and mebendazole are ubiquitously used, but t

48 Two benzimidazoles, albendazole and mebendazole, are currently used in STN m

49 inly focused on preventive chemotherapy with albendazole and mebendazole.

50 uld explain 79% of the observed effect, with albendazole and paroxetine as the predominant contributo

51 ubjects, who were assigned randomly into the albendazole and placebo arms, respectively.

52 ed study of the concurrent administration of albendazole and praziquantel was conducted in>1500 child

53 We recommend combined therapy with albendazole and prednisolone, with consideration for inc

54 ed for helminths, treated presumptively with albendazole and selectively with praziquantel, and monit

55 The patient was treated with albendazole and topical fumagillin and responded rapidly

56 either 4 repeated doses or a single dose of albendazole and were followed up during 13 months to ass

57 ngle-dose praziquantel, biannual single-dose albendazole) anthelminthic treatment on metabolic outcom

58 e-dose praziquantel, six-monthly single-dose albendazole) anthelminthic treatment on metabolic outcom

59 benzimidazole anthelmintics, mebendazole and albendazole, are commonly used to remove these infection

60 e sulfoxide (ASOX), the active metabolite of albendazole, are highly variable among patients.

61 er significantly from the CR of 13.4% in the albendazole arm (differences: 1.8%-points [95% confidenc

62 , we observed CRs of 15.3% in the moxidectin-albendazole arm and 22.5% in the ivermectin-albendazole

63 -albendazole arm and 22.5% in the ivermectin-albendazole arm, which did not differ significantly from

64 The moxidectin-albendazole arms also revealed higher CRs and egg reduct

65 5 days of azithromycin, and a single dose of albendazole, as compared with standard prophylaxis (trim

66 oate at a single dose of 20 mg per kilogram; albendazole at a single dose of 400 mg; or mebendazole a

67 amodiaquine (SP-AQ), or no chemoprevention (albendazole) at a 1:1:1 ratio.

68 le oral dose of 5, 10, 15, 20, 25, or 30 mg; albendazole, at a single oral dose of 400 mg; or placebo

69 Two extraction strategies for albendazole, chloramphenicol, trimethoprim, enrofloxacin

70 lower in pooled ivermectin clusters than in albendazole clusters after 3 months (adjusted odds ratio

71 Ivermectin-albendazole combination has shown promising, but setting

72 The moxidectin-albendazole combination of 8 mg plus 400 mg should be in

73 8, 16, or 24 mg of moxidectin plus 400 mg of albendazole combination therapy; or placebo.

74 d those who were treated with ivermectin and albendazole [corrected].

75 In those where albendazole-corticosteroid co-therapy was used, 97.87% r

76 We evaluated whether moxidectin-albendazole could serve as an alternative to albendazole

77 eline mf prevalence and diethylcarbamazine + albendazole (DA) or ivermectin + diethylcarbamazine + al

78 istration (MDA) using diethylcarbamazine and albendazole (DA).

79 wo-drug combination (diethylcarbamazine plus albendazole [DA]) that is widely used in LF elimination

80 ive (quarterly single-dose praziquantel plus albendazole daily for 3 days) or standard (annual praziq

81 rachoma, with the newly approved ivermectin, albendazole, diethylcarbamazine (IDA) regime for Lymphat

82 A single 800-mg albendazole dose provides higher efficacy against hookwo

83 have demonstrated significant variability in albendazole effectiveness among people infected with the

84 Albendazole efficacy was good, but 19 of 48 treated pati

85 1:1) eligible participants to either empiric albendazole every 3 months plus praziquantel annually (t

86 atment with metronidazole, nitazoxanide, and albendazole failed to eradicate the infection.

87 ass drug administration with ivermectin plus albendazole for lymphatic filariasis cannot be applied i

88 groups also received diethylcarbamazine and albendazole for lymphatic filariasis control.

89 tion of praziquantel for schistosomiasis and albendazole for soil-transmitted helminths.

90 ations with higher efficacy than single-dose albendazole for T. trichiura, including albendazole-iver

91 ted with integrated MDA (of praziquantel and albendazole) for schistosomiasis and soil-transmitted he

92 otocage, including well-known agents such as Albendazole, Gemcitabine, Bosutinib, Neratinib, and Pona

93 6.36-9.85), whereas it did not change in the albendazole group (13.71%, 10.81-17.05, at 3 months vs 1

94 ticipants) and the observed cure rate in the albendazole group (17% [95% CI, 6 to 35]; 5 of 30 partic

95 s significantly lower in the ivermectin plus albendazole group (four [17%]), but there were no signif

96 nd geometric mean titer were observed in the albendazole group in subjects with non-O ABO blood group

97 CI, 46 to 88; 14 of 20 participants) in the albendazole group.

98 group and 2.66 per child-year at risk in the albendazole group; the adjusted incidence rate ratio (iv

99 Whereas albendazole had no effect on IR (estimated treatment eff

100 regimen (ivermectin, diethylcarbamazine, and albendazole) has been shown to clear the transmissible s

101 igible population annually with ivermectin + albendazole (IA) can achieve the 1% mf prevalence thresh

102 ior to three annual doses of ivermectin plus albendazole (IA) used in many LF endemic areas of Africa

103 o standard 3 annual doses of ivermectin plus albendazole (IA) used in many LF-endemic areas of Africa

104 apy with ivermectin, diethylcarbamazine, and albendazole (IDA) is much more effective against LF than

105 le (DA) or ivermectin + diethylcarbamazine + albendazole (IDA) treatment, elimination can be reached

106 e of ivermectin plus diethylcarbamazine plus albendazole [IDA] is noninferior to standard 3 annual do

107 ment (ivermectin with diethylcarbamazine and albendazole [IDA]) is superior to a two-drug combination

108 men (ivermectin plus diethylcarbamazine plus albendazole, IDA) is non-inferior to three annual doses

109 ity trial of biannual mass administration of albendazole in a village in Republic of the Congo.

110 Expanded use of albendazole in combination with ivermectin would ensure

111 and tolerability or combined ivermectin and albendazole in Haitian schoolchildren.

112 200 mug/kg to eligible livestock, or 400 mg albendazole in humans only (control) for 3 consecutive m

113 Women given albendazole in the second trimester of pregnancy had a l

114 of pathologic mass together with persistent albendazole intake.

115 , namely doxycycline, diethylcarbamazine and albendazole, intradermally.

116 Albendazole is a new, broad-spectrum antiparasitic drug,

117 Although albendazole is efficacious when long treatment schedules

118 Periodic treatment with albendazole is now used in many school-based intestinal

119 hese nematode species, e.g., the efficacy of albendazole is strong on A. ceylanicum but weak on H. ba

120 Moxidectin-albendazole is superior to moxidectin.

121 Albendazole is the drug of choice against hookworm.

122 dose albendazole for T. trichiura, including albendazole-ivermectin (RR of cure, 3.22 [95% confidence

123 lacebo (n=625), 40 mg/kg praziquantel and an albendazole-matching placebo (n=626), or an albendazole-

124 albendazole-matching placebo (n=626), or an albendazole-matching placebo and praziquantel-matching p

125 nual praziquantel plus 6 monthly single-dose albendazole) MDA.

126 pairwise comparison of drugs (praziquantel, albendazole, mebendazole, tribendimidine, or combination

127 albendazole could serve as an alternative to albendazole monotherapy in Cote d'Ivoire.

128 iagnosis of neuroangiostrongyliasis in which albendazole monotherapy was used, 100% reported high eff

129 200-400 micrograms/kg ivermectin and 400 mg albendazole (n = 24).

130 in (mean, 273 micrograms/kg, n = 28), 400 mg albendazole (n = 29), or a combination of 200-400 microg

131 Neither albendazole nor praziquantel treatments affected infant

132 ertical transmission was not associated with albendazole (odds ratio 0.70, 95% CI 0.35-1.42) or prazi

133 Treatment with either albendazole or ivermectin cured all patients with most r

134 All subjects received 4 rounds of albendazole or matching placebo with 3-month intervals,

135 Current MDA approaches using single-dose albendazole or mebendazole are effective for ascariasis,

136 dic mass drug administration (generally with albendazole or mebendazole) to at-risk populations and i

137 c-worm infections are typically treated with albendazole or mebendazole, but both drugs show low effi

138 nesia and assigned 954 households to receive albendazole or placebo once every 3 mo for 2 y.

139 e-blind study to receive two doses of either albendazole or placebo prior to vaccination and in a gro

140 ceive either 2 sequential doses of 400 mg of albendazole or placebo.

141 difference between the side effect rate from albendazole or the double placebo.

142 1.84-5.63]; dERR, 0.97 [95% CI, .21-1.74]), albendazole-oxantel pamoate (RR, 5.07 [95% CI, 1.65-15.5

143 among those who received both ivermectin and albendazole (p = 0.0001).

144 greater in the treatment group that received albendazole (P=.06).

145 ning or presumptive treatment with 400 mg of albendazole per day for five days.

146 Albendazole plus chloroquine achieved clinical and paras

147 rapy (100 mg 3 times per day for 5 days) and albendazole plus chloroquine combination therapy (400 mg

148 Albendazole plus chloroquine had a low cure rate in nitr

149 who clinically and parasitologically failed albendazole plus chloroquine treatment and opted for ret

150 30% of patients treated with quinacrine and albendazole plus chloroquine, respectively.

151 Albendazole plus diethylcarbamazine significantly reduce

152 than the widely used two-drug combinations (albendazole plus either ivermectin or diethylcarbamazine

153 Albendazole plus ivermectin significantly reduced preval

154 lumbricoides and investigated the effect of albendazole pretreatment on the postvaccination response

155 were less prevalent among those treated with albendazole (prevalence ratio, 0.60).

156 After implementation of the albendazole protocol, the most common pathogens among 17

157 Furthermore, albendazole, pyrimethamine, and penicillin demonstrate t

158 served CRs increased with ascending doses of albendazole reaching a maximum of 94.1% (95% CI, 80.3%-9

159 R, 1.14; 95% CI, 1.002-1.27), increased dose albendazole regime (RR, 1.26; 95% CI, 1.14-1.39), lower

160 : 1.14; 95% C.I. 1.002-1.27), increased dose albendazole regime (RR: 1.26; 95% C.I. 1.14-1.39), lower

161 nematode Caenorhabditis elegans (wild-type, albendazole-resistant, and ivermectin-resistant strains)

162 r the same moxidectin dosages plus 400 mg of albendazole, respectively; and 12% for placebo.

163 %, while two other multiple-dose regimens of albendazole resulted in high predicted cure rates: 300 m

164 Treatment with oxantel pamoate-albendazole resulted in higher cure and egg-reduction ra

165 fants of women who had received two doses of albendazole rose by 59 g (95% CI 19-98), and infant mort

166 g treatment with a single dose of ivermectin-albendazole, some of these defects were reversed, with m

167 Plasma levels of albendazole sulfoxide (ASOX), the active metabolite of a

168 as significantly higher with oxantel pamoate-albendazole than with mebendazole (31.2% vs. 11.8%, P=0.

169 omized 1:1:1 to 200 mg, 400 mg, or 600 mg of albendazole; the other age groups were randomized 1:1:1:

170 Presumptive albendazole therapy administered overseas before departu

171 The efficacy of albendazole therapy in patients with parenchymal neurocy

172 thesized that high ASOX plasma levels during albendazole therapy may be associated with an increased

173 Albendazole therapy was associated with favorable change

174 Following initiation of albendazole therapy, the index patient developed atrial

175 s surgical removal of the cyst and prolonged albendazole therapy.

176 ya were randomly assigned (1:1:1) to receive albendazole through annual school-based treatment target

177 Presumptive administration of albendazole to all immigrants at risk for parasitosis wo

178 International trials have shown albendazole to be safe and effective in eradicating many

179 strategy of biannual mass administration of albendazole to eliminate lymphatic filariasis in areas w

180 , and the addition of diethylcarbamazine and albendazole to scabies treatment.

181 es in IFN-gamma were significant only in the albendazole-treated A. lumbricoides infection group (P =

182 ls of IL-2 were significantly greater in the albendazole-treated group compared with the placebo grou

183 ated antigen 4 (CTLA-4) on CD4(+) T cells of albendazole-treated individuals, -0.060 [-0.107 to -0.01

184 After adjustment for sex, age, and region, albendazole-treated refugees were less likely than untre

185 Among 22,586 albendazole-treated refugees, only 4.7% had one or more

186 o effect on infectious disease incidence for albendazole treatment (malaria [hazard ratio 0.95, 95% C

187 Albendazole treatment of individuals with human immunode

188 hes the magnitude of this response, and that albendazole treatment prior to vaccination was able to p

189 infants of mothers with hookworm infection, albendazole treatment reduced interleukin-5 (geometric m

190 Albendazole treatment, compared with placebo, was associ

191 bjects and significantly decreased following albendazole treatment, there was no effect exerted by th

192 C recommendation of presumptive predeparture albendazole treatment.

193 samples before and after 1 year of 3-monthly albendazole treatment.

194 served immediately (within 15 minutes) after albendazole treatment.

195 were noted between targeted and nontargeted albendazole treatments for the variables measured at eac

196 renatal supplements, in which women received albendazole twice during pregnancy.

197 No serious adverse events associated with albendazole use were reported.

198 rterly single-dose praziquantel, triple dose albendazole) versus standard (annual single-dose praziqu

199 rterly single-dose praziquantel, triple-dose albendazole) vs standard (annual single-dose praziquante

200 Albendazole was administered in all the participants at

201 Albendazole was associated with a significant reduction

202 antimalarials when malaria-positive whereas albendazole was given in a targeted (n = 467; treatment

203 Empiric chemotherapy with albendazole was instituted and surgical en bloc removal

204 emia, combined treatment with ivermectin and albendazole was more effective than treatment with iverm

205 The 250 mg/kg Albendazole was served as control.

206 djusted incidence rate ratio (ivermectin vs. albendazole) was 0.74 (95% confidence interval [CI], 0.5

207 unity-wide MDA (a single oral dose of 400 mg albendazole) was delivered to all eligible individuals b

208 No adverse events related to albendazole were reported.

209 Moxidectin and its combination with albendazole were well tolerated.

210 ficacy and safety profile of oxantel pamoate-albendazole when used in the treatment of T. trichiura i

211 include diethylcarbamazine, ivermectin, and albendazole, which are used mostly in combination to red

212 Recommended therapy includes 400 mg of albendazole, which is moderately efficacious.

213 dicted CRs increased with ascending doses of albendazole, with a CR of 74.9% (95% confidence interval